Biology Reference
In-Depth Information
28. Ito S, Yoshimoto R, Miyamoto Y, Mitobe Y, Nakamura T, Ishihara A, et al. Detailed
pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
Eur J
Pharmacol
2006;
529
:40-6.
29. Pos Z, Wiener Z, Pocza P, Racz M, Toth S, Darvas Z, et al. Histamine suppresses
fibulin-5 and insulin-like growth factor-II receptor expression in melanoma.
Cancer
Res
2008;
68
:1997-2005.
30. Williams C. cAMP detection methods in HTS: selecting the best from the rest.
Nat Rev
Drug Discov
2004;
3
:125-35.
31. Jean A, Conductier G, Manrique C, Bouras C, Berta P, Hen R, et al. Anorexia induced
by activation of serotonin 5-HT4 receptors is mediated by increases in CART in the
nucleus accumbens.
Proc Natl Acad Sci USA
2007;
104
:16335-40.
32. Chambers C, Smith F, Williams C, Marcos S, Liu ZH, Hayter P, et al. Measuring in-
tracellular calcium fluxes in high throughput mode.
Comb Chem High Throughput Screen
2003;
6
:355-62.
33. Ayoub MA, Trinquet E, Pfleger KD, Pin JP. Differential association modes of
the thrombin receptor PAR1 with Galphai1, Galpha12, and beta-arrestin 1.
FASEB J
2010;
24
:3522-35.
34. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al. Independent beta-
arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular
signal-regulated kinases 1 and 2.
Proc Natl Acad Sci USA
2003;
100
:10782-7.
35. Holloway AC, Qian H, Pipolo L, Ziogas J, Miura S, Karnik S, et al. Side-chain
substitutions within angiotensin II reveal different requirements for signaling, internal-
ization, and phosphorylation of
type 1A angiotensin receptors.
Mol Pharmacol
2002;
61
:768-77.
36. Violin JD, Lefkowitz RJ. Beta-arrestin-biased ligands at seven-transmembrane receptors.
Trends Pharmacol Sci
2007;
28
:416-22.
37. Horton RA, Vogel KW. Multiplexing terbium- and europium-based TR-FRET read-
outs to increase kinase assay capacity.
J Biomol Screen
2010;
15
:1008-15.
38. Zhang R, Xie X. Tools for GPCR drug discovery.
Acta Pharmacol Sin
2012;
33
:372-84.
39. Leopoldo M, Lacivita E, Berardi F, Perrone R. Developments in fluorescent probes for
receptor research.
Drug Discov Today
2009;
14
:706-12.
40. Middleton RJ, Kellam B. Fluorophore-tagged GPCR ligands.
Curr Opin Chem Biol
2005;
9
:517-25.
41. Baker JG, Middleton R, Adams L, May LT, Briddon SJ, Kellam B, et al. Influence of
fluorophore and linker composition on the pharmacology of fluorescent adenosine
A1 receptor ligands.
Br J Pharmacol
2010;
159
:772-86.
42. Middleton RJ, Briddon SJ, Cordeaux Y, Yates AS, Dale CL, George MW, et al. New
fluorescent adenosine A1-receptor agonists that allow quantification of ligand-receptor
interactions in microdomains of single living cells.
J Med Chem
2007;
50
:782-93.
43. Monnier C, Tu H, Bourrier E, Vol C, Lamarque L, Trinquet E, et al. Trans-activation
between 7TM domains: implication in heterodimeric GABAB receptor activation.
EMBO J
2011;
30
:32-42.
44. Albizu L, Teppaz G, Seyer R, Bazin H, Ansanay H, Manning M, et al. Toward efficient
drug screening by homogeneous assays based on the development of new fluorescent
vasopressin and oxytocin receptor ligands.
J Med Chem
2007;
:4976-85.
45. Hu LA, Zhou T, Hamman BD, Liu Q. A homogeneous G protein-coupled receptor
ligand binding assay based on time-resolved fluorescence resonance energy transfer.
Assay Drug Dev Technol
2008;
6
:543-50.
46. Hinner MJ, Johnsson K. How to obtain labeled proteins and what to do with them.
Curr
Opin Biotechnol
2010;
21
:766-76.
47. Damoiseaux R, Keppler A, Johnsson K. Synthesis and applications of chemical probes
for human O6-alkylguanine-DNA alkyltransferase.
Chembiochem
2001;
2
:285-7.
50
Search WWH ::
Custom Search